A team of Australian researchers have developed a new targeted therapeutic approach that could improve treatment for ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...

Vivere Oncotherapies, a UC Berkeley spin-out developing cancer therapies that activate the immune system to detect and destroy cancer cells in immunologically cold tumors, today announced over $10M in ...

Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic ...

Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

Inhibrx Biosciences, Inc. stays a Strong Buy with Q2 2026 ozekibart BLA catalyst, 2026 PFS data, and Ewing sarcoma updates.

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...

Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...

Michael Wang, MD, highlights several notable abstracts from ASH 2025 that collectively underscore continued progress in ...

Colon cancer treatment is personalized based on stage, overall health and tumor characteristics. Early detection and accurate ...